PHOENIX – October 21, 2019 /Canna Newswire/ – This week Cannasphere Biotech introduced a lineup of nanoliposomal CBD beverage powers in three refreshing flavors, powered by the company’s patent pending Lipofusion™ delivery technologies. The initially 3 flavors out there are:
- Passionfruit Citrus
- Ginger Lemonade
- Blueberry Chill
“The flavor possibilities are practically limitless and these Lipofusion CBD beverage powders develop a refreshing, enjoyable CBD practical experience.” mentioned Star Simmons, president of Cannasphere. “Consumers yearn for the promises that CBD holds so they place up with unpalatable tinctures or powders, or add additional capsules to their pill routine. That is not required any longer. Just add any of these fantastic-tasting CBD beverage powders to water, shake, sip and appreciate.”
According to Simmons, these flavored CBD beverage powders, powered by Lipofusion, are out there for private label and can be packaged in practical single-serving stick packs or pouches with 30 or 60 servings, containing 10 or 20 mg of nanoliposomal CBD per serving. The corporation also gives custom formulation solutions for brands that would like to create their personal custom flavors and maybe add other synergistic actives, such as Vitamin C, curcumin, or melatonin, that combine properly with CBD.
“While the industry is becoming crowded with ineffectual CBD goods, it is essential to set your brand apart by supplying CBD goods that get final results. Our Lipofusion delivery technologies makes it possible for CBD brands to do that,” mentioned Andrew Wood, biochemistry advisor for Cannasphere. “Lipofusion technologies utilizes nanoliposomal encapsulation to facilitate speedy onset and sustained release to make sure customers basically really feel the distinction and appreciate lasting added benefits.”
In truth, Forbes published an report on October 1st showcasing a current pharmacokinetic study demonstrating that nanoliposomes are the most optimal way to provide CBD to the human physique. Cannasphere’s hemp-derived, water-soluble CBD goods are broad spectrum and formulated applying patent pending nanoliposomal delivery technologies known as Lipofusion to optimize bioavailability and assimilation of cannabinoids at the cellular level. Learn additional at www.lipofusion.com.
“When customers get outstanding final results, they turn into extremely loyal to a specific brand—they may well even turn into brand evangelists. That translates into repeat sales as properly as word-of-mouth buzz,” added Simmons.
To get free of charge samples of each and every flavor pay a visit to: https://www.cannaspherebiotech.com/samples/
About Cannasphere Biotech
Cannasphere Biotech combines the energy of Cannabidiol (CBD) with its proprietary major edge Lipofusion delivery technologies to maximize efficacy and provide outstanding, trustworthy added benefits. The corporation gives unflavored manufacturing-prepared Lipofusion CBD powder and a selection of private-label CBD goods such as flavored CBD beverage powders. For additional facts please pay a visit to www.cannaspherebiotech.com.
About Cannabidiol (CBD)
According to CBDProject.com, the excitement about Cannabidiol (CBD) and its numerous wellness added benefits is steadily growing worldwide. Scientific and clinical investigation worldwide underscores the prospective of CBD as an efficient medicinal agent intended to assistance wellbeing. CBD is presently getting studied as an adjunct therapy for a wide variety of circumstances such as arthritis, diabetes, alcoholism, MS, chronic discomfort, schizophrenia, PTSD, depression, antibiotic-resistant infections, epilepsy, and other neurological problems.[1,2,3] CBD has demonstrable neuroprotective properties and is a concentrate for anti-cancer investigation at numerous US and international academic investigation centers. [1,2,3,4]
Cannabis Cannabinoid Res. 2017 two(1): 139–154.Published on line 2017 Jun 1. doi: 10.1089/can.2016.0034
Perm J. 2019 23: 18-041.Published on line 2019 Jan 7. doi: 10.7812/TPP/18-041
Cannabis Cannabinoid Res. 2018 three(1): 152–161.Published on line 2018 Jul 1. doi: 10.1089/can.2018.0006
Surg Neurol Int. 2018 9: 91.Published on line 2018 Apr 26. doi: 10.4103/sni.sni_45_18
# CNW #
Media Make contact with: